Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.

about

CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia

P2860

Q55409636-05ED4E06-BC0B-4F74-9F90-A90D38E256EB Q59126098-E54D43D9-A029-4837-B486-C7134E180DAB

P2860

Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.

Item

http://www.wikidata.org/entity/Q38690757

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Modelling the cost-effectivene ...... ctions in a Norwegian setting.

@en

type

Item

label

Modelling the cost-effectivene ...... ctions in a Norwegian setting.

@en

prefLabel

Modelling the cost-effectivene ...... ctions in a Norwegian setting.

@en

P1476

Modelling the cost-effectivene ...... ctions in a Norwegian setting.

@en

P2093

Max Korman

http://www.w3.org/2001/XMLSchema#string

Torbjørn Wisløff

http://www.w3.org/2001/XMLSchema#string

P2860

PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Cost-effectiveness of additional catheter-directed thrombolysis for deep vein thrombosis.

Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.

P304

15-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EHJCVP/PVX010

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28444187

http://www.w3.org/2001/XMLSchema#string

P932

5843101

http://www.w3.org/2001/XMLSchema#string

Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.

about

P2860

P2860

Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932